Objective

IndicatorData components and sourceLikely report date/Implementation Plan
HBV 1
To reduce hepatitis B infections
1.Incidence of hepatitis B
Modelling based on notifications of acute hepatitis B, serological prevalence surveys and population flows2011
Victorian Infectious Diseases Reference Laboratory to produce estimates for year 2010 for inclusion in 2011 report.
Kirby Institute to establish, by end Quarter 1 2012, a Hepatitis B Projections Working Group to oversee production and annual updating of a validated dynamic mathematical model of HBV transmission in Australia. Working Group to agree on scope, inputs, assumptions, resources required, intended outcomes and complexity, to produce models for 2012 report onward.
2.Coverage of hepatitis B vaccination at 12 and 24 months12 month coverage assessment:
Numerator: Number of children in the relevant birth cohort who have been administered dose three of hepatitis B vaccine by 12 months of age recorded on the Australian Childhood Immunisation Register (ACIR)

Denominator: Number of children turning 12 months of age in the measurement year on the ACIR

24 month coverage assessment:
Numerator: Number of children in the relevant cohort who have dose three hepatitis B vaccine administered by 24 months of age recorded on the ACIR

Denominator: Number of children turning 24 months of age in the measurement year on the ACIR
2011
HBV 2
To reduce the proportion of people with chronic hepatitis B who have not been diagnosed
1.Estimated proportion of people with chronic hepatitis B who have not been diagnosedModelling based on notifications of hepatitis B, serological prevalence surveys and population flows2012
Kirby Institute to establish, by end Quarter 1 2012, a Hepatitis B Projections Working Group to oversee production and annual updating of a validated dynamic mathematical model of HBV transmission in Australia. Working Group to agree on scope, inputs, assumptions, resources required, intended outcomes and complexity, to produce models for 2012 onward.
2.Notifications of newly acquired and unspecified hepatitis Number of notifications of newly acquired hepatitis B and of unspecified hepatitis B to National Notifiable Diseases Surveillance System

Analysis: Age, gender, Aboriginality, country of birth (for jurisdictions where available)
2011
3.Proportion of people who die from hepatocellular carcinoma within 12 months of hepatitis B diagnosisNumerator: Number of hepatitis B cases who die from hepatocellular carcinoma within 12 months of hepatitis B diagnosis, identified by linking jurisdictional hepatitis B data to cancer registries

Denominator: Number of notifications of unclassified hepatitis B to jurisdictional notifiable disease databases
Currently not available
Numerator: Kirby Institute to consider options for data collection for this indicator

Denominator: See HBV2.2 numerator
HBV 3
To improve the health and wellbeing of people with chronic hepatitis B, through access to clinical services, screening , treatment, education and support
1.Proportion of people with chronic hepatitis B who are screened every six months for hepatocellular carcinoma Numerator: Number of people with chronic hepatitis B who meet the criteria for screening who are screened every six months for hepatocellular carcinoma
Denominator: Estimated number of people with chronic hepatitis B who meet the criteria for screening, obtained from modelling
Currently not available
Numerator: Kirby Institute to consider options for data collection for this indicator

Denominator: See HBV1.1
2.Proportion of hepatocellular carcinoma attributable to hepatitis BNumerator: Number of new cases of hepatocellular carcinoma among people infected with hepatitis B, identified by linking jurisdictional hepatitis B data to cancer registries
Denominator: Number of new cases of hepatocellular carcinoma reported to cancer registries
Currently not available
Numerator: Kirby Institute to consider options for data collection for this indicator

Denominator: Kirby Institute to collate hepatocellular carcinoma data from state cancer registries
3.Proportion of people with chronic hepatitis B dispensed drugs for hepatitis B infection through the Highly Specialised Drugs Program Numerator: Number of individuals dispensed medications for hepatitis B infection through Highly Specialised Drugs Program

Denominator: Estimated number of people with chronic hepatitis B, obtained from modelling based on notifications of acute hepatitis B, serological prevalence surveys and population flows
2011 (numerator data only; denominator currently not available)
Numerator: Kirby Institute to negotiate arrangements with Medicare for the routine release of Highly Specialised Drugs Program data, by end 2011. (See also HCV 4)

Denominator: As per HBV 1.1
Kirby Institute to explore potential for model to be refined at a later stage so that the denominator is the number indicated for treatment, by end Quarter 1 2012.